Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases

Open access
Chhetri, Dhani Raj · 2019 · Frontiers in Pharmacology

Abstract

Myo inositol has been established as an important growth promoting factor of mammalian cells and animals. The role of myo-inositol as a lipotropic factor has been proven in addition to its involvement as co-factors of enzymes and as messenger molecules in signal transduction. Myo-inositol deficiency leads to intestinal lipodystrophy in animals and ‘inositol-less-death’ in some fungi. Of late, diverse uses of myo-inositol and its derivatives have been found in medicinal research. These compounds are used in a variety of ailments starting from diabetes to cancer and continued research in this direction promises a new future in therapeutics. In different diseases, inositols implement different strategies for therapeutic actions like tissue specific increase or decrease in inositol products, production of IPGs, conversion of MI to DCI, modulation of signal transduction, regulation of ROS production etc. Though inositol pharmacology is a relatively lesser known field still recent years have generated a critical mass of information on the subject. This review aims to summarize our current understanding on the role of inositol derivatives in ameliorating the symptoms of different diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2019.01172

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Chhetri, D. R.
Venue
Frontiers in Pharmacology
Published
2019-10-11
Volume
10
Pages
1172-1172
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2979841773
Cited by
192
References
8
FWCI
4.65
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.